Bio-equivalence of IR Tablet against ER Tablet [Design Issues]

posted by Jasim Uddin – Bangladesh, 2018-06-20 11:29 (899 d 09:50 ago) – Posting: # 18929
Views: 1,906

Dear Sirs

Does anyone know about BE Study design of Immediate Release Formulation against Extended Release Formulation?

We manufacture Potassium Chloride 600 mg IR tablet. But no RLD is available as IR tablet. RLD SLOW-K 600 mg of Novartis is available as ER tablet.

Is it possible to design BE study of our IR formulation of Potassium Chloride 600 mg against SLOW-K 600 mg ER tablet?

Would appreciate kind advice of the experts in this forum.

Kind regards

Jasim

Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

Activity
 Admin contact
21,243 posts in 4,431 threads, 1,483 registered users;
online 7 (0 registered, 7 guests [including 2 identified bots]).
Forum time: Saturday 21:19 UTC (Europe/Vienna)

I believe there is no philosophical high-road in science,
with epistemological signposts. No, we are in a jungle
and find our way by trial and error,
building our road behind us as we proceed.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5